Melanoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Melanoma – Pipeline Review, H2 2016’, provides an overview of the Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Melanoma

The report reviews pipeline therapeutics for Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Melanoma therapeutics and enlists all their major and minor projects

The report assesses Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Melanoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Melanoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AB Science SA

AbbVie Inc

Abivax SA

Acetylon Pharmaceuticals Inc

Adamis Pharmaceuticals Corp

Adaptimmune Therapeutics Plc

Adicet Bio Inc

Aduro BioTech Inc

Advanced Cancer Therapeutics

Advaxis Inc

Aeterna Zentaris Inc

Affichem SA

Agalimmune Ltd

Agenus Inc

Agilvax Inc

AGV Discovery SAS

AIMM Therapeutics BV

Alethia Biotherapeutics Inc

Altor BioScience Corp

Amgen Inc

Anavex Life Sciences Corp

Angimmune LLC

Antibe Therapeutics Inc

Antigen Express Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

APO-T BV

Apogenix GmbH

Aposense Ltd

Aptose Biosciences Inc

Arisaph Pharmaceuticals Inc

ARMO Biosciences Inc

Array BioPharma Inc

Asana BioSciences LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Azaya Therapeutics Inc

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bayer AG

BeiGene Ltd

Beijing Kawin Technology Share-Holding Co Ltd

Bellicum Pharmaceuticals Inc

BerGenBio AS

Bio-Cancer Treatment International Ltd

Biocad

Biogazelle NV

Biogenomics Ltd

BioLineRx Ltd

Bioncotech Therapeutics SL

Bionomics Ltd

BioNTech AG

Biothera Pharmaceutical Inc

Biovista Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

Can-Fite BioPharma Ltd

CCRP Therapeutics GmbH

Cellceutix Corp

Celldex Therapeutics Inc

Celprogen Inc

Celyad SA

Checkmate Pharmaceuticals Inc

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co Ltd

Cipher Pharmaceuticals Inc

Cornerstone Pharmaceuticals Inc

Cortice Biosciences Inc

Corvus Pharmaceuticals Inc

CytomX Therapeutics Inc

Cytune Pharma SAS

CyTuVax BV

CZ BioMed Corp

Daiichi Sankyo Company Ltd

Deciphera Pharmaceuticals LLC

DEKK-TEC Inc

Dicerna Pharmaceuticals Inc

DormaTarg Inc

Dynavax Technologies Corp

Eisai Co Ltd

Eli Lilly and Company

Elsalys Biotech SAS

Ensol Biosciences Inc

EntreChem SL

eTheRNA Immunotherapies NV

Evelo Therapeutics Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faes Farma SA

Five Prime Therapeutics Inc

Formune SL

Galapagos NV

Galectin Therapeutics Inc

Genelux Corp

Genocea Biosciences Inc

Genzyme Corp

GlaxoSmithKline Plc

Gradalis Inc

GreenPeptide Co Ltd

Hadasit Medical Research Services & Development Ltd

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

Heat Biologics Inc

HEC Pharm Co Ltd

Hemispherx Biopharma Inc

Histogen Inc

Horizon Pharma Plc

Humorigin Biotechnology Corp

Idera Pharmaceuticals Inc

Ignyta Inc

Immodulon Therapeutics Ltd

Immune Design Corp

Immune Response BioPharma Inc

ImmunGene Inc

Immunocore Ltd

ImmunoGen Inc

Immupharma Plc

ImmuRx Inc

IMPACT Therapeutics Inc

Imugene Ltd

Incuron LLC

Incyte Corp

Infinity Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

InteRNA Technologies BV

IO Biotech ApS

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

KaloBios Pharmaceuticals Inc

Kancera AB

Karyopharm Therapeutics Inc

Kite Pharma Inc

Kura Oncology Inc

Lentigen Technology Inc

Life Science Pharmaceuticals Inc

Lindis Biotech GmbH

Lion Biotechnologies Inc

Lipotek Pty Ltd

Loxo Oncology, Inc.

Lupin Ltd

Lytix Biopharma AS

MacroGenics Inc

Magnus Life Ltd

MaxiVAX SA

MediaPharma srl

Medicenna Therapeutics Inc

MedImmune LLC

Medisyn Technologies Inc

Medivation Inc

MELEMA Pharma GmbH

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Modulate Therapeutics Inc

Molecular Templates Inc

Moleculin Biotech Inc

Morphotek Inc

Nektar Therapeutics

Neonc Technologies Inc

Nerviano Medical Sciences Srl

Neumedicines Inc

NewLink Genetics Corp

NormOxys Inc

Northwest Biotherapeutics Inc

Novartis AG

Novogen Ltd

Omeros Corp

Oncology Research International Ltd

Oncolys BioPharma Inc

Oncolytics Biotech Inc

OncoNOx ApS

OncoSec Medical Inc

OncoTartis Inc

Oncovir Inc

Onxeo SA

Orega Biotech SAS

OSE Immunotherapeutics

Pacific Northwest Biotechnology LLC

Patrys Ltd

PepTx Inc

PepVax Inc

Pfizer Inc

Pharmicell Co Ltd

Pharminox Ltd

Pharmis Biofarmaceutica Lda

Philogen SpA

PinCell srl

Pivotal BioSciences Inc

Plexxikon Inc

Polaris Pharmaceuticals Inc

Polyplus-Transfection SA

Prima BioMed Ltd

Propanc Health Group Corp

Provectus Biopharmaceuticals Inc

Provenance Biopharmaceuticals Corp

Qu Biologics Inc

Reata Pharmaceuticals Inc

Recepta Biopharma SA

Recombio SL

Rexahn Pharmaceuticals Inc

Rgenix Inc

Rigontec GmbH

RXi Pharmaceuticals Corp

Sapvax

SATT North SAS

Scancell Holdings Plc

SilaGene Inc

Sillajen Biotherapeutics

SolaranRx Inc

Sorrento Therapeutics Inc

Spotlight Innovation Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Susavion Biosciences Inc

SuviCa Inc

Syndax Pharmaceuticals Inc

Taiga Biotechnologies Inc

TaiRx Inc

Taiwan Liposome Company Ltd

Takara Bio Inc

Takeda Pharmaceutical Company Ltd

Takis Srl

Tara Immuno-Oncology Therapeutics LLC

Targovax ASA

TC BioPharm Ltd

TetraLogic Pharmaceuticals

Theravectys SA

Tikcro Technologies Ltd

TILT Biotherapeutics Ltd

Tiltan Pharma Ltd

Tocagen Inc

TREAT U SA

TVAX Biomedical Inc

TyrNovo Ltd

UbiVac LLC

Ultimovacs AS

UNC Health Care

Vaccibody AS

Vascular Biogenics Ltd

Vault Pharma Inc

Vaxenta Biotechnologies

Vichem Chemie Research Ltd

Viralytics Ltd

ViraTherapeutics GmbH

Virttu Biologics Ltd

VLP Therapeutics LLC

WntResearch AB

X4 Pharmaceuticals Inc

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 13

Melanoma Overview 14

Therapeutics Development 15

Melanoma - Therapeutics under Development by Companies 17

Melanoma - Therapeutics under Investigation by Universities/Institutes 38

Melanoma - Pipeline Products Glance 43

Melanoma - Products under Development by Companies 47

Melanoma - Products under Investigation by Universities/Institutes 76

Melanoma - Companies Involved in Therapeutics Development 82

Melanoma - Therapeutics Assessment 338

Drug Profiles 391

Melanoma - Dormant Projects 1537

Melanoma - Discontinued Products 1580

Melanoma - Product Development Milestones 1585

Appendix 1598

List of Tables

List of Tables

Number of Products under Development for Melanoma, H2 2016 72

Number of Products under Development for Melanoma – Comparative Analysis, H2 2016 73

Number of Products under Development by Companies, H2 2016 74

Number of Products under Development by Companies, H2 2016 (Contd..1) 75

Number of Products under Development by Companies, H2 2016 (Contd..2) 76

Number of Products under Development by Companies, H2 2016 (Contd..3) 77

Number of Products under Development by Companies, H2 2016 (Contd..4) 78

Number of Products under Development by Companies, H2 2016 (Contd..5) 79

Number of Products under Development by Companies, H2 2016 (Contd..6) 80

Number of Products under Development by Companies, H2 2016 (Contd..7) 81

Number of Products under Development by Companies, H2 2016 (Contd..8) 82

Number of Products under Development by Companies, H2 2016 (Contd..9) 83

Number of Products under Development by Companies, H2 2016 (Contd..10) 84

Number of Products under Development by Companies, H2 2016 (Contd..11) 85

Number of Products under Development by Companies, H2 2016 (Contd..12) 86

Number of Products under Development by Companies, H2 2016 (Contd..13) 87

Number of Products under Development by Companies, H2 2016 (Contd..14) 88

Number of Products under Development by Companies, H2 2016 (Contd..15) 89

Number of Products under Development by Companies, H2 2016 (Contd..16) 90

Number of Products under Development by Companies, H2 2016 (Contd..17) 91

Number of Products under Development by Companies, H2 2016 (Contd..18) 92

Number of Products under Development by Companies, H2 2016 (Contd..19) 93

Number of Products under Development by Companies, H2 2016 (Contd..20) 94

Number of Products under Investigation by Universities/Institutes, H2 2016 95

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 96

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 97

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 98

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 99

Comparative Analysis by Late Stage Development, H2 2016 100

Comparative Analysis by Clinical Stage Development, H2 2016 101

Comparative Analysis by Early Stage Development, H2 2016 102

Comparative Analysis by Unknown Stage Development, H2 2016 103

Products under Development by Companies, H2 2016 104

Products under Development by Companies, H2 2016 (Contd..1) 105

Products under Development by Companies, H2 2016 (Contd..2) 106

Products under Development by Companies, H2 2016 (Contd..3) 107

Products under Development by Companies, H2 2016 (Contd..4) 108

Products under Development by Companies, H2 2016 (Contd..5) 109

Products under Development by Companies, H2 2016 (Contd..6) 110

Products under Development by Companies, H2 2016 (Contd..7) 111

Products under Development by Companies, H2 2016 (Contd..8) 112

Products under Development by Companies, H2 2016 (Contd..9) 113

Products under Development by Companies, H2 2016 (Contd..10) 114

Products under Development by Companies, H2 2016 (Contd..11) 115

Products under Development by Companies, H2 2016 (Contd..12) 116

Products under Development by Companies, H2 2016 (Contd..13) 117

Products under Development by Companies, H2 2016 (Contd..14) 118

Products under Development by Companies, H2 2016 (Contd..15) 119

Products under Development by Companies, H2 2016 (Contd..16) 120

Products under Development by Companies, H2 2016 (Contd..17) 121

Products under Development by Companies, H2 2016 (Contd..18) 122

Products under Development by Companies, H2 2016 (Contd..19) 123

Products under Development by Companies, H2 2016 (Contd..20) 124

Products under Development by Companies, H2 2016 (Contd..21) 125

Products under Development by Companies, H2 2016 (Contd..22) 126

Products under Development by Companies, H2 2016 (Contd..23) 127

Products under Development by Companies, H2 2016 (Contd..24) 128

Products under Development by Companies, H2 2016 (Contd..25) 129

Products under Development by Companies, H2 2016 (Contd..26) 130

Products under Development by Companies, H2 2016 (Contd..27) 131

Products under Development by Companies, H2 2016 (Contd..28) 132

Products under Investigation by Universities/Institutes, H2 2016 133

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 134

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 135

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 136

Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 137

Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 138

Melanoma – Pipeline by 4SC AG, H2 2016 139

Melanoma – Pipeline by AB Science SA, H2 2016 140

Melanoma – Pipeline by AbbVie Inc, H2 2016 141

Melanoma – Pipeline by Abivax SA, H2 2016 142

Melanoma – Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 143

Melanoma – Pipeline by Adamis Pharmaceuticals Corp, H2 2016 144

Melanoma – Pipeline by Adaptimmune Therapeutics Plc, H2 2016 145

Melanoma – Pipeline by Adicet Bio Inc, H2 2016 146

Melanoma – Pipeline by Aduro BioTech Inc, H2 2016 147

Melanoma – Pipeline by Advanced Cancer Therapeutics, H2 2016 148

Melanoma – Pipeline by Advaxis Inc, H2 2016 149

Melanoma – Pipeline by Aeterna Zentaris Inc, H2 2016 150

Melanoma – Pipeline by Affichem SA, H2 2016 151

Melanoma – Pipeline by Agalimmune Ltd, H2 2016 152

Melanoma – Pipeline by Agenus Inc, H2 2016 153

Melanoma – Pipeline by Agilvax Inc, H2 2016 154

Melanoma – Pipeline by AGV Discovery SAS, H2 2016 155

Melanoma – Pipeline by AIMM Therapeutics BV, H2 2016 156

Melanoma – Pipeline by Alethia Biotherapeutics Inc, H2 2016 157

Melanoma – Pipeline by Altor BioScience Corp, H2 2016 158

Melanoma – Pipeline by Amgen Inc, H2 2016 159

Melanoma – Pipeline by Anavex Life Sciences Corp, H2 2016 160

Melanoma – Pipeline by Angimmune LLC, H2 2016 161

Melanoma – Pipeline by Antibe Therapeutics Inc, H2 2016 162

Melanoma – Pipeline by Antigen Express Inc, H2 2016 163

Melanoma – Pipeline by APEIRON Biologics AG, H2 2016 164

Melanoma – Pipeline by Apexigen Inc, H2 2016 165

Melanoma – Pipeline by Aphios Corp, H2 2016 166

Melanoma – Pipeline by APO-T BV, H2 2016 167

Melanoma – Pipeline by Apogenix GmbH, H2 2016 168

Melanoma – Pipeline by Aposense Ltd, H2 2016 169

Melanoma – Pipeline by Aptose Biosciences Inc, H2 2016 170

Melanoma – Pipeline by Arisaph Pharmaceuticals Inc, H2 2016 171

Melanoma – Pipeline by ARMO Biosciences Inc, H2 2016 172

Melanoma – Pipeline by Array BioPharma Inc, H2 2016 173

Melanoma – Pipeline by Asana BioSciences LLC, H2 2016 174

Melanoma – Pipeline by Astellas Pharma Inc, H2 2016 175

Melanoma – Pipeline by Astex Pharmaceuticals Inc, H2 2016 176

Melanoma – Pipeline by AstraZeneca Plc, H2 2016 177

Melanoma – Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 178

Melanoma – Pipeline by Azaya Therapeutics Inc, H2 2016 179

Melanoma – Pipeline by Basilea Pharmaceutica Ltd, H2 2016 180

Melanoma – Pipeline by Batu Biologics Inc, H2 2016 181

Melanoma – Pipeline by Bayer AG, H2 2016 182

Melanoma – Pipeline by BeiGene Ltd, H2 2016 183

Melanoma – Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016 184

Melanoma – Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 185

Melanoma – Pipeline by BerGenBio AS, H2 2016 186

Melanoma – Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 187

Melanoma – Pipeline by Biocad, H2 2016 188

Melanoma – Pipeline by Biogazelle NV, H2 2016 189

Melanoma – Pipeline by Biogenomics Ltd, H2 2016 190

Melanoma – Pipeline by BioLineRx Ltd, H2 2016 191

Melanoma – Pipeline by Bioncotech Therapeutics SL, H2 2016 192

Melanoma – Pipeline by Bionomics Ltd, H2 2016 193

Melanoma – Pipeline by BioNTech AG, H2 2016 194

Melanoma – Pipeline by Biothera Pharmaceutical Inc, H2 2016 195

Melanoma – Pipeline by Biovista Inc, H2 2016 196

Melanoma – Pipeline by Boehringer Ingelheim GmbH, H2 2016 197

Melanoma – Pipeline by Boston Biomedical Inc, H2 2016 198

Melanoma – Pipeline by Bristol-Myers Squibb Company, H2 2016 199

Melanoma – Pipeline by Calithera Biosciences Inc, H2 2016 200

Melanoma – Pipeline by Can-Fite BioPharma Ltd, H2 2016 201

Melanoma – Pipeline by CCRP Therapeutics GmbH, H2 2016 202

Melanoma – Pipeline by Cellceutix Corp, H2 2016 203

Melanoma – Pipeline by Celldex Therapeutics Inc, H2 2016 204

Melanoma – Pipeline by Celprogen Inc, H2 2016 205

Melanoma – Pipeline by Celyad SA, H2 2016 206

Melanoma – Pipeline by Checkmate Pharmaceuticals Inc, H2 2016 207

Melanoma – Pipeline by Chipscreen Biosciences Ltd, H2 2016 208

Melanoma – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 209

Melanoma – Pipeline by Cipher Pharmaceuticals Inc, H2 2016 210

Melanoma – Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 211

Melanoma – Pipeline by Cortice Biosciences Inc, H2 2016 212

Melanoma – Pipeline by Corvus Pharmaceuticals Inc, H2 2016 213

Melanoma – Pipeline by CytomX Therapeutics Inc, H2 2016 214

Melanoma – Pipeline by Cytune Pharma SAS, H2 2016 215

Melanoma – Pipeline by CyTuVax BV, H2 2016 216

Melanoma – Pipeline by CZ BioMed Corp, H2 2016 217

Melanoma – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 218

Melanoma – Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 219

Melanoma – Pipeline by DEKK-TEC Inc, H2 2016 220

Melanoma – Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 221

Melanoma – Pipeline by DormaTarg Inc, H2 2016 222

Melanoma – Pipeline by Dynavax Technologies Corp, H2 2016 223

Melanoma – Pipeline by Eisai Co Ltd, H2 2016 224

Melanoma – Pipeline by Eli Lilly and Company, H2 2016 225

Melanoma – Pipeline by Elsalys Biotech SAS, H2 2016 226

Melanoma – Pipeline by Ensol Biosciences Inc, H2 2016 227

Melanoma – Pipeline by EntreChem SL, H2 2016 228

Melanoma – Pipeline by eTheRNA Immunotherapies NV, H2 2016 229

Melanoma – Pipeline by Evelo Therapeutics Inc, H2 2016 230

Melanoma – Pipeline by Exelixis Inc, H2 2016 231

Melanoma – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 232

Melanoma – Pipeline by Faes Farma SA, H2 2016 233

Melanoma – Pipeline by Five Prime Therapeutics Inc, H2 2016 234

Melanoma – Pipeline by Formune SL, H2 2016 235

Melanoma – Pipeline by Galapagos NV, H2 2016 236

Melanoma – Pipeline by Galectin Therapeutics Inc, H2 2016 237

Melanoma – Pipeline by Genelux Corp, H2 2016 238

Melanoma – Pipeline by Genocea Biosciences Inc, H2 2016 239

Melanoma – Pipeline by Genzyme Corp, H2 2016 240

Melanoma – Pipeline by GlaxoSmithKline Plc, H2 2016 241

List of Figures

List of Figures

Number of Products under Development for Melanoma, H2 2016 72

Number of Products under Development for Melanoma – Comparative Analysis, H2 2016 73

Number of Products under Development by Companies, H2 2016 74

Number of Products under Investigation by Universities/Institutes, H2 2016 95

Comparative Analysis by Late Stage Development, H2 2016 100

Comparative Analysis by Clinical Stage Development, H2 2016 101

Comparative Analysis by Early Stage Products, H2 2016 102

Assessment by Monotherapy Products, H2 2016 395

Assessment by Combination Products, H2 2016 396

Number of Products by Top 10 Targets, H2 2016 397

Number of Products by Stage and Top 10 Targets, H2 2016 397

Number of Products by Top 10 Mechanism of Actions, H2 2016 421

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 421

Number of Products by Top 10 Routes of Administration, H2 2016 444

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 444

Number of Products by Top 10 Molecule Types, H2 2016 446

Number of Products by Stage and Top 10 Molecule Types, H2 2016 446

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports